Spotlight on AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix®)

BioDrugs

Volumn 25, Issue 4, 2011, Pages 265-269

  McKeage, Kate ^a   Romanowski, Barbara ^b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Adis Spotlights; Human papillomavirus vaccine

Indexed keywords

ALUMINUM HYDROXIDE; AS 04; IMMUNOLOGICAL ADJUVANT; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

CELLULAR IMMUNITY; CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FOLLOW UP; HEADACHE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMORAL IMMUNITY; IMMUNOGENICITY; INJECTION SITE PAIN; MYALGIA; PAPILLOMAVIRUS INFECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; VIRUS LIKE AGENT;

ADJUVANTS, IMMUNOLOGIC; ALUMINUM HYDROXIDE; CERVICAL INTRAEPITHELIAL NEOPLASIA; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; LIPID A; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL DISEASES; UTERINE CERVICAL NEOPLASMS;

EID: 80051543007     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.2165/11206830-000000000-00000     Document Type: Review

References (41)

1. Deschuyteneer M, Elouahabi A, Plainchamp D, et al. Molecular and structural characterization of the L1 virus-like particles that are used as vaccine antigens in Cervarix™ the AS04-adjuvanted HPV-16 and -18 cervical cancer vaccine. Hum Vaccines 2010; 6 (5): 407-19
2. Stanley M, Lowy DR, Frazer I. Prophylactic HPV vaccines: underlying mechanisms. Vaccine 2006 Aug 21; 24 Suppl. 3: S106-13 (Pubitemid 44293025)
3. Schwarz TF, Leo O. Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature. Gynecol Oncol 2008 Sep; 110 (3 Suppl. 1): S1-10
4. Stanley M. Immune responses to human papillomavirus. Vaccine 2006 Mar 30; 24 Suppl. 1: S16-22
5. Garcon N, Van Mechelen M, Wettendorff M. Development and evaluation of AS04, a novel and improved adjuvant system containingMPLand aluminium salt. In: Schijns V, O'Hagan D, editors. Immunopotentiators in modern vaccines. London: Elsevier Academic Press, 2006: 161-77
6. Martin M, Michalek SM, Katz J. Role of innate immune factors in the adjuvant activity of monophosphoryl lipid A. Infect Immun 2003; 71 (5): 2498-507 (Pubitemid 36519862)
7. Arbyn M, Dillner J. Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening. J Clin Virol 2007; 38 (3): 189-97 (Pubitemid 46275523)
8. Harper DM. Prevention of human papillomavirus infections and associated diseases by vaccination: a new hope for global public health. Public Health Genomics 2009; 12: 319-30
9. The GlaxoSmithKline Vaccine HPV-007 Study Group, Romanowski B, Colares de Borba P, et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009 Dec 12; 374 (9706): 1975-85
10. Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women [published erratum appears in Lancet 2010; 376: 1054]. Lancet 2009 Jul 25; 374 (9686): 301-14
11. De Carvalho N, Teixeira J, Roteli-Martins CM, et al. Sustained efficacy and immunogenicity of theHPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine 2010 Aug 31; 28 (38): 6247-55
12. Roteli-Martins CM, Naud P, Borba P, et al. Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: follow-up to 8.4 years [poster]. 28th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2010 May 4-8; Nice
13. David MP, Van Herck K, Hardt K, et al. Long-term persistence of anti-HPV- 16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses. Gynecol Oncol 2009 Dec; 115 (3 Suppl.): S1-6
14. Moscicki B, Wheeler CM, Romanowski B, et al. Anamnestic response elicited by a fourth dose of the HPV-16/18 AS04-adjuvanted vaccine in young women [abstract no. SS 11-6]. European Research Organisation on Genital Infection and Neoplasia (EUROGIN); 2010 Feb 17-20; Monte Carlo
15. Kemp T, Hildesheim A, Safaeian M, et al. HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection [abstract].26th International Papillomavirus Conference; 2010 Jul 3-8; Montreal (QC)
16. Moscicki B, Wheeler C, Romanowski B, et al. Anamnestic response to nonvaccine types elicited by a fourth dose of the HPV-16/18 AS04-adjuvanted vaccine [abstract no. SS 3-4]. European Research Organisation on Genital Infection and Neoplasia (EUROGIN); 2010 Feb 17-20; Monte Carlo
17. Pedersen C, Petaja T, Strauss G, et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health 2007 Jun; 40 (6): 564-71 (Pubitemid 46771257)
18. Schwarz TF, Spaczynski M, Schneider A, et al. Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years. Vaccine 2009 Jan; 27 (4): 581-7
19. Petaja T, HPV-012 Study Group. Long-term persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in preteen/adolescent girls and young women [abstract no. P IM-3]. European Research Organisation on Genital Infection and Neoplasia (EUROGIN); 2010 Feb 17-20; Monte Carlo
20. Schwarz TF, Spaczynski M, Schneider A, et al. Long-term persistence of immune response to HPV-16/18 AS04-adjuvanted cervical vaccine in women aged 15-55 years [abstract]. Asia Oceania Research Organization on Genital Infections and Neoplasia (AOGIN); 2010 Mar 26-28; New Delhi
21. KonnoR,DobbelaereKO, GodeauxOO, et al. Immunogenicity, reactogenicity, and safety of human papillomavirus 16/18AS04-adjuvanted vaccine in Japanese women: interim analysis of a phase II, double-blind, randomized controlled trial at month 7. Int J Gynecol Cancer 2009 Jul; 19 (5): 905-11
22. Bhatla N, Suri V, Basu P, et al. Immunogenicity and safety of human papillomavirus- 16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women. J Obstet Gynaecol Res 2010 Feb; 36 (1): 123-32
23. Lim BK, Ng KY, Omar J, et al. Cervical cancer prevention with the human papillomavirus-16/18 AS04-adjuvanted vaccine: immunogenicity and safety in 18-35 years old Malaysian women [oral presentation no. 105926]. 4th Biennial Meeting of the Asia Oceanic Research Organisation on Genital Infection and Neoplasia (AOGIN); 2010 Mar 26-28; New Delhi
24. Einstein MH, Baron M, Levin MJ, et al. Comparison of the immunogenicity and safety of Cervarix™ and Gardasil® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccines 2009; 5 (10): 705-19
25. Garcia-Sicilia J, Schwarz TF, Carmona A, et al. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine coadministered with combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine to girls and young women. J Adolesc Health 2010 Feb; 46 (2): 142-51
26. Schmeink C, Bekkers RLM, Josefsson A, et al. Co-administration of AS04- adjuvanted human papillomavirus-16/18 vaccine with hepatitis B vaccine in healthy female subjects aged 9-15 years: month 7 data [abstract]. 28th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2010 May 4-8; Nice
27. Poppe W, Paavonen J, Naud P, et al. Vaccine efficacy with/without evidence of prior HPV-16/18 infection: analysis of PATRICIA, a phase III trial with AS04-adjuvanted HPV-16/18 vaccine [abstract no. 1388]. 16th International Meeting of the European Society of Gynaecological Oncology; 2009 Oct 11-14; Belgrade
28. Safaeian M, Porras C, Schiffman M, et al. Epidemiological study of anti- HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections. J Natl Cancer Inst 2010 Nov 3; 102 (21): 1653-62
29. Hildesheim A, Herrero R, Wacholder S, et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 2007 Aug 15; 298 (7): 743-53 (Pubitemid 47263157)
30. Castellsague X. Risk of new infection with the same HPV-type in women with naturally-acquired HPV-16/18 antibodies [abstract no. 44]. 13th Biennial Meeting of the International Gynecologic Cancer Society (IGCS); 2010 Oct 23-26; Prague
31. Romanowski B. Clinical benefit of the AS04-adjuvanted human papillomavirus (HPV)-16/18 vaccine against CIN2+ related to the 5 most common oncogenic HPV types: PATRICIA[abstract no. 808]. 47th Annual Meeting of the Infectious Diseases Society of America (IDSA); 2009 Oct 29-Nov 1; Philadelphia (PA)
32. Descamps D, Hardt K, Spiessens B, et al. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum Vaccines 2009 May; 5 (5): 332-40
33. European Medicines Agency. Cervarix™ suspension for injection. Human papillomavirus vaccine [types 16,18] (recombinant, adjuvanted, adsorbed): summary of product characteristics [online]. Available from URL: http:// ema.europa.eu/ [Accessed 2010 Sep 12]
34. Gauthier A, Martin-Escudero V, Moore L, et al. Long-term clinical impact of introducing a human papillomavirus 16/18 AS04 adjuvant cervical cancer vaccine in Spain. Eur J Public Health 2008 Dec; 18 (6): 674-80
35. Kohli M, Ferko N, Martin A, et al. Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK. Br J Cancer 2007 Jan 15; 96 (1): 143-50 (Pubitemid 46094653)
36. Torvinen S, Nieminen P, Lehtinen M, et al. Cost effectiveness of prophylactic HPV 16/18 vaccination in Finland: results from a modelling exercise. J Med Econ 2010; 13 (2): 284-94
37. La Torre G, de Waure C, Chiaradia G, et al. The Health Technology Assessment of bivalent HPV vaccine Cervarix™ in Italy. Vaccine 2010 Apr 26; 28 (19): 3379-84
38. Rogoza RM, Westra TA, Ferko N, et al. Cost-effectiveness of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: adaptation of an existing cohort model to the situation in the Netherlands. Vaccine 2009; 27 (35): 4776-83
39. Diaz M, de Sanjose S, Ortendahl J, et al. Cost-effectiveness of human papillomavirus vaccination and screening in Spain. Eur J Cancer 2010; 46: 2973-85
40. Dee A, Howell F. A cost-utility analysis of adding a bivalent or quadrivalent HPV vaccine to the Irish cervical screening programme. Eur J Public Health 2010; 20 (2): 213-9
41. McKeage K, Romanowski B. AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix™): a review of its use in the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types. Drugs 2011; 71 (4): 465-88